Dasatinib News and Research

RSS

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

Therapeutic effect of imatinib improved with addition of chloroquine

The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation.

13 Apr 2009

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today.

29 Mar 2009

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Researcher develops method for early detection of leukemia relapse

Researchers at the Fred Hutchinson Cancer Research Center have developed a method that allows for the early detection of a common mechanism of resistance on drug treatment for chronic myeloid leukemia.

10 Jul 2008

Bosutinib safe, effective for chronic myelogenous leukemia

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

12 Dec 2007

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Updated clinical trial results show that the drug dasatinib (Sprycel) continues to be highly effective in patients with chronic myelogenous leukemia who were unable to tolerate Gleevec or who developed resistance to it, reports a team led by researchers at Dana-Farber Cancer Institute.

12 Dec 2007

New role for miRNA in leukemia discovered

Scientists here have found that mini-molecules called micro-RNA may play a critical role in the progression of chronic myeloid leukemia (CML) from its more treatable chronic phase to a life-threatening phase, called blast crisis.

10 Dec 2007

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

10 Dec 2007

Fingolimod shows promise in 2 lethal leukemias

A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia.

29 Aug 2007

Combination of drugs might decrease the chance of chronic myeloid leukemia returning

Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL).

17 Aug 2007

Dasatinib shows promise as first treatment for chronic myelogenous leukemia

An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

5 Jun 2007

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib), a new oral treatment for patients with chronic myeloid leukemia (CML),

29 Jun 2006

New leukemia drug gives renewed hope to those battling drug resistance to the disease

New research offers hope for victims of chronic myeloid leukemia (CML) battling drug resistance to the disease.

18 Jun 2006

Dasatinib offers new options for leukemia patients

Dasatinib, an experimental drug under development by Bristol-Myers Squibb, reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec, which is considered the standard of treatment for the disorder.

14 Jun 2006

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.

11 Apr 2006